News

Next-Day Effects: Are Medications Leaving Drivers at Risk?

COMPLIANCE WITH 2017 FDA GUIDANCE FOR EVALUATING DRUG-IMPAIRED DRIVING Prescription and over-the-counter drugs can save…

cogres1December 18, 2024

Inside CRC

World Mental Health Day 2024

Celebrating Progress in Mental Health Care On World Mental Health Day, we reflect on the…

cogres1October 10, 2024

Collaboration Success Stories

Two FDA Approvals to Advance Migraine Care

Proactive Mitigation to Support Program Success Learn how CRC’s proactive approach and real-time data oversight…

cogres1October 1, 2024

Breaking News

CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors

Cognitive Research Corporation (CRC), a leading CNS-focused clinical research organization, proudly announces the addition of…

cogres1September 24, 2024

Collaboration Success Stories

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

Overcoming Obstacles to Bring a New Standard of Care Discover how CRC’s approach helped a…

cogres1September 17, 2024

Collaboration Success Stories

FDA Approval: Novel Formulation for Treatment of Schizophrenia

Driving FDA Approvals with Precision and Speed Discover how CRC’s expertise in clinical trial management…

cogres1September 11, 2024

Collaboration Success Stories

Phase I Studies: On Time with Quality Data

Consistent Early Phase Milestone Achievement Backed by select partnerships with Phase I Specialty Units and…

cogres1June 24, 2024

Collaboration Success Stories

Tight Timelines: The Biotech Existence

First Patient In 6 Weeks from Written Award Learn how CRC partnered with an emerging…

cogres1June 20, 2024

Breaking News

CRC Appoints Dr. Tom Zoda as Chief Executive Officer

Cognitive Research Corporation (“CRC”), a leading Central Nervous System (CNS)-focused clinical research and drug development…

cogres1January 11, 2024

Tom Zoda, Ph.D., Chairs ASCP 2026 Panel on Preventable Failure Risk in CNS Clinical Trials

Why Driving Impairment Evaluation Is Becoming More Important in CNS Drug Development

Research Rising: Clinical Trials Day 2026

Next-Day Effects: Are Medications Leaving Drivers at Risk?

World Mental Health Day 2024

Two FDA Approvals to Advance Migraine Care

CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

FDA Approval: Novel Formulation for Treatment of Schizophrenia

Phase I Studies: On Time with Quality Data

Tight Timelines: The Biotech Existence

CRC Appoints Dr. Tom Zoda as Chief Executive Officer

Call Us

Get Support

Visit Us

About Us

Therapeutic Expertise

CRO Services

Driving Simulation

Meet Our Team

Careers

Clinical Trial Management

Trial Design

Data Management

Quality Assurance

Biostatistics

Medical Writing

Rater Services

Stay Connected with CRC

Own the Questions.

Lead the Outcome.

Join our Newsletter